NEVVI Medicare utilization intelligence

← back

AHMED, AISHAM.D. NPI 1730341850 Clinician

Hematology-Oncology · TUCSON, AZ

Specialty Hematology-Oncology — from billed Medicare claims
In practice about 22 years since medical school (class of 2004, self-reported to CMS)
Location TUCSON, AZ · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 46 codes billed · 60,277 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
TMC MEDICAL NETWORK
2025–2026
ARIZONA ONCOLOGY ASSOCIATES PC
2020–2025
ASCENSION MEDICAL GROUP-NORTHERN WISCONSIN, INC
2019

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2022-03

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
J9271 Injection, pembrolizumab, 1 mg
J9267 Injection, paclitaxel, 1 mg
J1453 Injection, fosaprepitant, 1 mg
J0185 Injection, aprepitant, 1 mg
J9025 Injection, azacitidine, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1437 Injection, ferric derisomaltose, 10 mg
J1626 Injection, granisetron hydrochloride, 100 mcg
J0897 Injection, denosumab, 1 mg
J2469 Injection, palonosetron hcl, 25 mcg
96375 Injection of additional new drug or substance into vein
J9395 Injection, fulvestrant, 25 mg
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
J9045 Injection, carboplatin, 50 mg
96413 Administration of chemotherapy into vein, 1 hour or less
96372 Injection of drug or substance under skin or into muscle
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
J3489 Injection, zoledronic acid, 1 mg
J7030 Infusion, normal saline solution , 1000 cc
J9060 Injection, cisplatin, powder or solution, 10 mg
36591 Collection of blood sample from implanted device
96417 Administration of additional new drug or substance into vein, 1 hour or less
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96415 Administration of chemotherapy into vein, each additional hour
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96361 Infusion into a vein for hydration, each additional hour
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J1200 Injection, diphenhydramine hcl, up to 50 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96360 Infusion into a vein for hydration, 31-60 minutes
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
J3490 Unclassified drugs
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
96374 Injection of drug or substance into vein
96411 Administration of additional new drug or substance into vein using push technique
96523 Irrigation of implanted venous access drug delivery device
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.